A study in mice suggests that targeting peptidyl arginine deiminases in lupus patients may have a therapeutic role in T cell-mediated diseases, affecting innate and adaptive immunity, as well as modulating dysregulated toll-like receptor 7-dependent immune responses…
![](https://www.the-rheumatologist.org/wp-content/uploads/2015/09/ACR_SystemicLupusErythematosus_500x270-150x150.jpg)